Evidence map›Paper›PMID 34068551›Full record

ReviewMedicina (Kaunas, Lithuania)2021

Current Overview of Osteogenesis Imperfecta.

Mari Deguchi, Shunichiro Tsuji, Daisuke Katsura, Kyoko Kasahara, Fuminori Kimura, Takashi Murakami

Open access · goldAbstract readReview
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 97 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. [Comprehensive considerations for the diagnosis, treatment, and management of osteogenesis imperfecta].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mari DeguchiDepartment of Obstetrics & Gynecology, Shiga University of Medical Science, Otsu 520-2192, Shiga, Japan.
Shunichiro TsujiDepartment of Obstetrics & Gynecology, Shiga University of Medical Science, Otsu 520-2192, Shiga, Japan.ORCID 0000-0003-3945-6817
Daisuke KatsuraDepartment of Obstetrics & Gynecology, Shiga University of Medical Science, Otsu 520-2192, Shiga, Japan.ORCID 0000-0002-5357-5700
Kyoko KasaharaDepartment of Obstetrics & Gynecology, Shiga University of Medical Science, Otsu 520-2192, Shiga, Japan.
Fuminori KimuraDepartment of Obstetrics & Gynecology, Shiga University of Medical Science, Otsu 520-2192, Shiga, Japan.
Takashi MurakamiDepartment of Obstetrics & Gynecology, Shiga University of Medical Science, Otsu 520-2192, Shiga, Japan.
Shiga University of Medical Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteogenesis imperfecta (OI), or brittle bone disease, is a heterogeneous disorder characterised by bone fragility, multiple fractures, bone deformity, and short stature. OI is a heterogeneous disorder primarily caused by mutations in the genes involved in the production of type 1 collagen. Severe OI is perinatally lethal, while mild OI can sometimes not be recognised until adulthood. Severe or lethal OI can usually be diagnosed using antenatal ultrasound and confirmed by various imaging modalities and genetic testing. The combination of imaging parameters obtained by ultrasound, computed tomography (CT), and magnetic resource imaging (MRI) can not only detect OI accurately but also predict lethality before birth. Moreover, genetic testing, either noninvasive or invasive, can further confirm the diagnosis prenatally. Early and precise diagnoses provide parents with more time to decide on reproductive options. The currently available postnatal treatments for OI are not curative, and individuals with severe OI suffer multiple fractures and bone deformities throughout their lives. In utero mesenchymal stem cell transplantation has been drawing attention as a promising therapy for severe OI, and a clinical trial to assess the safety and efficacy of cell therapy is currently ongoing. In the future, early diagnosis followed by in utero stem cell transplantation should be adopted as a new therapeutic option for severe OI.

Indexed as

Mesenchymal Stem Cell TransplantationOsteogenesis ImperfectaAdultCollagen Type IFemaleGenetic TestingHumansMutationPregnancyCollagen Type Igenetic testingmesenchymal stem cell transplantationosteogenesis imperfectaskeletal dysplasia prenatal diagnosis

Identifiers

PMID34068551
PMCPMC8151368
OpenAlexW3163170306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.